



THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket Nos. 71369.172 and PFI-024)


In re Application of: Blumenberg et al.)
Serial No. 09/659,737)
Filing Date: September 11, 2000)
Examiner: Monshipouri
Group Art Unit: 1652

For: GENES AND POLYNUCLEOTIDES ASSOCIATED WITH ULTRAVIOLET RADIATION-MEDIATED SKIN DAMAGE AND USES THEREOF

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date below.

Date: 4/30/04


Sharon Matthews

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants submit herewith the references on the attached form PTO-1449, copies of which are enclosed. This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97 (d), after the mailing of a Notice of Allowance. Pursuant to 37 C.F.R. § 1.97 (e)(1), each cited reference was first cited in a communication (copy enclosed) from a foreign patent office on a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

This submission does not represent that a search has been made and does not constitute an admission that the listed documents are material to the patentability of the invention, or that the listed documents are prior art. Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application. If it should be determined that any of the listed documents constitute prior art under United States law, Applicants reserve the right to present to the Office relevant facts and law regarding the significance of such documents to the patentability of the claimed invention.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449 with the next Patent Office communication.


Supplemental Information Disclosure Statement
Appln. No. 09/659,737
Page 2

Please charge any fees that might be due in connection with this matter to Deposit Account Number 08-0219. If there are any questions, please call the undersigned at the telephone number indicated below.

Respectfully submitted,

Date: 4/30/04
HALE AND DORR LLP
60 State Street
Boston, MA 02109
(617) 526-6000
(617) 526-5000 (Facsimile)

Ann-Louise Kerner
Ann-Louise Kerner, Ph.D.
Reg. No. 33,523
Attorney/Agent for Applicants



Subt. For, PTO-1449				Docket Number 71369.172		Application Number 09/659,737	
INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)				Applicant Blumenberg et al.			
				Filing Date September 11, 2000		Group Art Unit 1652	
Sheet	1	OF	1				

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

Foreign Patent Documents							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)		
	B16	Broun et al., "Catalytic Plasticity of Fatty Acid Modification Enzymes Underlying Chemical Diversity of Plant Lipids," Science, Vol. 282, Nov 13, 1998, pp 1315-1317
	B17	Ng et al., "Point Mutation in the Second Phosphatase Domain of CD45 Abrogates Tyrosine Phosphatase Activity," Biochemical and Biophysical Research Communications," Vol. 206, No. 1, Jan 5, 1995, pp 302-309

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	